Last reviewed · How we verify
Ortho-Novum 777
Ortho-Novum 777 is a triphasic oral contraceptive that prevents pregnancy through hormonal suppression of ovulation.
Ortho-Novum 777 is a triphasic oral contraceptive that prevents pregnancy through hormonal suppression of ovulation. Used for Contraception / prevention of pregnancy.
At a glance
| Generic name | Ortho-Novum 777 |
|---|---|
| Sponsor | NYU Langone Health |
| Drug class | Triphasic oral contraceptive |
| Target | Progesterone receptor, estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | Phase 3 |
Mechanism of action
This combination oral contraceptive contains varying doses of norethindrone and ethinyl estradiol across three phases of the menstrual cycle, mimicking natural hormone fluctuations. The progestin and estrogen work synergistically to inhibit the luteinizing hormone (LH) surge required for ovulation, thicken cervical mucus to impede sperm transport, and alter the endometrium to prevent implantation.
Approved indications
- Contraception / prevention of pregnancy
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ortho-Novum 777 CI brief — competitive landscape report
- Ortho-Novum 777 updates RSS · CI watch RSS
- NYU Langone Health portfolio CI